Atossa Therapeutics (ATOS) 10-Q 14 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	7-May-14
Document Information [Line Items]	'	'
Entity Registrant Name	'ATOSSA GENETICS INC	'
Entity Central Index Key	'0001488039	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'ATOS	'
Entity Common Stock, Shares Outstanding	'	24,428,568
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets	'	'
Cash and cash equivalents	$16,590,951	$6,342,161
Accounts receivable, net	91,416	139,072
Prepaid expense	1,017,766	932,588
Total current assets	17,700,133	7,413,821
Fixed assets	'	'
Furniture and equipment, net	129,942	163,147
Total fixed assets	129,942	163,147
Other assets	'	'
Security deposit	61,309	36,446
Intangible assets, net	4,491,707	4,395,633
Total other assets	4,553,016	4,432,079
Total assets	22,383,091	12,009,047
Current liabilities	'	'
Accounts payable	0	9,634
Accrued expenses	744,736	637,986
Deferred rent	35,023	48,157
Payroll liabilities	195,896	476,477
Contingent liabilities	96,201	211,493
Other current liabilities	10,189	23,649
Total current liabilities	1,082,045	1,407,396
Stockholders' Equity	'	'
Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding	0	0
Common stock - $.001 par value; 75,000,000 shares authorized, 24,428,568 and 18,574,334 shares issued and outstanding	24,429	18,574
Additional paid-in capital	44,204,762	31,099,691
Accumulated deficit	-22,928,145	-20,516,614
Total stockholders' equity	21,301,046	10,601,651
Total liabilities and stockholders' equity	$22,383,091	$12,009,047

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized	75,000,000	75,000,000
Common stock, shares issued	24,428,568	18,574,334
Common stock, shares outstanding	24,428,568	18,574,334

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		59 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Revenue	'	'	'
Diagnostic testing services	$24,124	$169,230	$908,644
Product sales	0	13,440	231,380
Total revenue	24,124	182,670	1,140,024
Cost of revenue	'	'	'
Diagnostic testing services	0	47,599	141,509
Product sales	0	18,865	244,919
Total cost of revenue	0	66,464	386,428
Loss on obsolete inventory & LCM	0	0	271,856
Gross profit	24,124	116,206	481,740
Selling expenses	237,838	272,575	2,135,505
Research and development expenses	422,503	220,192	5,084,999
General and administrative expenses	1,774,708	1,564,872	16,155,879
Total operating expenses	2,435,049	2,057,639	23,376,383
Operating loss	-2,410,925	-1,941,433	-22,894,643
Interest income	143	0	7,026
Interest expense	749	7	40,280
Net loss before income taxes	-2,411,531	-1,941,440	-22,927,897
Income taxes	0	0	248
Net loss	($2,411,531)	($1,941,440)	($22,928,145)
Loss per common share - basic and diluted (in dollars per share)	($0.10)	($0.14)	($2.16)
Weighted average shares outstanding, basic & diluted (in shares)	24,419,060	13,421,119	10,604,575

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		59 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net loss	($2,411,531)	($1,941,440)	($22,928,145)
Common shares issued for services	0	155,969	249,279
Compensation cost for stock options granted	230,181	274,512	1,966,205
Loss on reduction on obsolete inventory and LCM	0	0	271,856
Impairment loss on long-life assets	0	'	158,292
Loan initiation fee accrued for notes payable	0	0	2,000
Depreciation and amortization	125,097	98,945	744,206
Contingent loss	'	0	211,493
Bad debt expense	27,860	0	382,721
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'	'
Decrease (Increase) in accounts receivable	19,796	-117,675	-474,137
Increase in inventory	0	'	-271,856
Increase in prepaid expenses	-245,178	-90,789	-425,805
Increase in security deposits	-24,863	0	-61,309
Decrease in accounts payable	-9,634	-33,626	0
Decrease (Increase) in accrued payroll	-280,581	94,371	195,896
Decrease (Increase) in deferred rent	-13,134	0	35,023
Decrease (Increase) in accrued expenses	106,750	279,951	789,736
Decrease in contingent loss liability	-115,292	0	-115,292
Decrease (Increase) in other current liabilities	-13,460	-55,030	10,189
Net cash used in operating activities	-2,603,989	-1,334,812	-19,259,648
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Purchase of furniture & fixtures	-2,966	0	-438,455
Purchase of software	-100,000	-8,500	-425,839
Net cash used in investing activities	-102,966	-8,500	-864,294
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Net proceeds from issuance of common stock and warrants	12,955,745	1,003,314	36,716,893
Repayments of loans from related parties	0	0	-2,000
Net cash provided by financing activities	12,955,745	1,003,314	36,714,893
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS	10,248,790	-339,998	16,590,951
CASH & CASH EQUIVALENTS, BEGINNING BALANCE	6,342,161	1,725,197	0
CASH & CASH EQUIVALENTS, ENDING BALANCE	16,590,951	1,385,199	16,590,951
SUPPLEMENTAL DISCLOSURES:	'	'	'
Interest paid	749	2,682	33,816
Income taxes paid	0	0	248
NONCASH INVESTING AND FINANCING ACTIVITIES:	'	'	'
Common stock and warrants issued for asset purchase	'	0	4,674,853
Noncash reclass of prepaid license fees	15,000	0	15,000
Options issued for previously accrued director compensation	0	0	45,000
Commitment shares distributed for capital contribution	0	2,387,250	3,137,500
Amortization of commitment shares	$75,000	$79,575	$2,560,540

NATURE_OF_OPERATIONS

NATURE OF OPERATIONS	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	NOTE 1: NATURE OF OPERATIONS
	Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 in the State of Delaware. The Company was formed to develop and market the Mammary Aspirate Specimen Cytology Test System, or MASCT System, which is a medical device that collects specimens of nipple aspirate fluid (NAF).   The Company’s fiscal year ends on December 31st.
	In December 2011, the Company established The National Reference Laboratory for Breast Health, Inc., or NRLBH, as a wholly-owned subsidiary. NRLBH is the Company’s CLIA-certified laboratory which performs our NAF cytology test on NAF specimens including those collected with the MASCT System. The current version of the MASCT System, is called the ForeCYTE Breast Aspirator. The NRLBH is developing other tests such as the ArgusCYTE test, on blood samples from breast cancer survivors to detect circulating tumor cells.
	In September 2012, the Company acquired the assets of Acueity Healthcare, Inc. (“Acueity”). The purchased assets included intellectual property rights related to the Viaduct Miniscope and accessories, the Manoa Breast Biopsy system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories, and cash in the amount of $400,000. The microendoscopes are less than 0.9 mm outside diameter and can be inserted into a milk duct. This permits a physician to pass a microendoscope into the milk duct system of the breast and view the duct system via fiberoptic video images. Abnormalities that are visualized can then be biopsied from inside the duct with the biopsy tools that are inserted adjacent to the microendoscope. The acquired patents relate to intraductal diagnostic and therapeutic devices and methods of use. The Company did not, however, acquire an inventory of these diagnostic tools, manufacturing capabilities or any personnel to market and sell the tools. The Company cannot provide any assurance that it will be successful commercializing these tools.
	Development Stage Risk
	From April 30, 2009 (inception) through March 31, 2014, the Company earned $1,140,024 in revenue from the sale of its MASCT Systems and laboratory services. The Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”, which was previously Statement of Financial Accounting Standards No. 7 (“SFAS 7”). Among the disclosures required by ASC 915 are that the Company’s financial statements be identified as those of a development stage company, and that the statements of operations, stockholders’ equity and cash flows disclose activity since the date of the Company’s inception.
	Since its inception, the Company has been dependent upon the receipt of capital investment to fund its continuing activities. In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plan will be successfully executed. The Company’s ability to execute its business plan will depend on its ability to obtain additional financing and achieve a profitable level of operations. There can be no assurance that sufficient financing will be obtained. Further, the Company cannot give any assurance that it will generate substantial revenue or that its business operations will prove to be profitable.

GOING_CONCERN

GOING CONCERN	3 Months Ended
	Mar. 31, 2014
Going Concern Disclosure [Abstract]	'
Going Concern Disclosure [Text Block]	'
	NOTE 2: GOING CONCERN
	The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
	Management’s Plan to Continue as a Going Concern
	In order to continue as a going concern, the Company will need additional capital resources. Management’s plans to obtain such resources for the Company include (1) obtaining capital from the sale of its equity securities, (2) sales of the MASCT System, which is now called the ForeCYTE Breast Aspirator, and laboratory service revenue , and (3) short-term or long-term borrowings from banks, stockholders or other party(ies) when needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.
	The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.

SUMMARY_OF_ACCOUNTING_POLICIES

SUMMARY OF ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 3: SUMMARY OF ACCOUNTING POLICIES
	Basis of Presentation:
	The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiary NRLBH. All significant intercompany account balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.
	Recently Issued Accounting Pronouncements:
	The Company has adopted all recently issued accounting pronouncements that management believes to be applicable to the Company. The adoption of these accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.
	Revenue Recognition:
	Overview
	The Company recognizes product and service revenue in accordance with GAAP when the following overall fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or the service has been performed, (iii) the Company’s price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.
	Product Revenue
	The Company recognizes revenue for sales of the MASCT kits and devices on an accrual basis for sales to distributors when the above four criteria are met. For sales of MASCT kits and devices directly to physicians, the revenue is typically recognized upon receipt of cash as the Company has an insufficient sales history on which to determine the collectability. Shipping documents and the completion of any customer acceptance requirements, when applicable, will be used to verify product delivery. The Company will assess whether a price is fixed or determinable based upon the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. For sales directly to physicians, once a history of sales and collectability has been established, the Company will recognize revenue on an accrual basis with an offsetting reserve for doubtful accounts based on the history during the initial sales period.
	Service Revenue
	The Company records revenue for diagnostic testing on an accrual basis at the Medicare allowed and invoiced amount. Amounts invoiced above the Medicare amount, namely non-Medicare, are not recognized on an accrual basis and instead are recognized on a cash basis as received. Diagnostic testing revenue at the Medicare rate is recognized upon completion of the test, communication of results to the patient’s physician, and when collectability is reasonably assured. Customer purchase orders and/or contracts are generally used to determine the existence of an arrangement. Once the Company has historical sales and can determine the proper amount to recognize as uncollectible, it will then begin to recognize the entire amount, both Medicare and non-Medicare billing on an accrual basis, with an offsetting allowance for doubtful accounts recorded based on history.
	Cost of Revenue:
	Cost of revenue consists of cost of diagnostic testing services and cost of product sales. Cost of diagnostic testing services primarily includes direct cost of material, direct labor, equipment, and shipping to process the patient samples (including pathology, quality control analysis, and shipping charges to transport tissue sample) in our laboratory. Costs associated with performing the Company's tests are recorded as tests are processed. Costs recorded for tissue sample processing and shipping charges represent the cost of all the tests processed during the period regardless of whether revenue was recognized with respect to that test. Cost of product sales primarily includes manufacturing cost of our MASCT System for sales to distributors, which is recorded upon transfer of ownership of the goods.
	Cash and Cash Equivalents:
	Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.
	Use of Estimates:
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
	Accounts Receivable:
	Accounts receivable are recorded at net realizable value consisting of the carrying amount less allowance for doubtful accounts, as needed. The Company assesses the collectability of accounts receivable based primarily upon the creditworthiness of the customer as determined by credit checks and analysis, as well as the customer’s payment history. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company’s allowance for doubtful accounts as of March 31, 2014 and December 31, 2013 was $382,721 and $354,861, respectively.
	Inventories:
	The Company’s inventories are stated at lower of cost or market. Cost is determined on a moving-average basis. Costs of inventories include purchase and related costs incurred in delivering the products to their present location and condition. Market value is determined by reference to selling prices after the balance sheet date or to management’s estimates based on prevailing market conditions. Inherent in the lower of cost or market calculation are several significant judgments based on a review of the aging of the inventory, inventory movement of products, economic conditions, and replacement costs. Management periodically evaluates the composition of its inventories at least quarterly to identify slow-moving and obsolete inventories to determine if any valuation allowance is required. During the course of our recall commenced in October 2013, we have recalled a substantial number of MASCT Systems. Based on management’s assessment of those devices and the pending FDA clearance, management decided to establish 100% allowance for valuation reserve on all MASCT Systems, and recorded $149,946 of losses on obsolete inventory for the year ended December 31, 2013. During March 31, 2014, management identified no additional slow moving or obsolete inventory. The Company outsources product manufacturing to outside manufacturer contactors.  The ownership of the goods transfers from the manufacturer to the Company’s customer at the time the products are shipped to the customers. As of March 31, 2014 and December 31, 2013, inventories amounted to $0 after netting of the above valuation allowance.
	The Company provides, either directly or through distributors, the NAF specimen collection kits to doctors with our MASCT System for doctors to collect specimens that are returned to the NRLBH or other laboratories for diagnostic analysis. These collection kits are considered part of the MASCT System. The Company’s direct sales personnel distributes the kits directly to physicians free of charge, or by offering a rebate to physicians. The Company has not intended to deem the kits as a primary product line due to their nominal cost and value per unit. As a result, the kits are immediately expensed and recorded as selling expense upon purchasing of the kits.
	Property, plant, and equipment:
	Property, plant and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.
	Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Machinery and equipment		5
	Leasehold improvements		2.083
	The Company applies the provisions of FASB ASC Topic 360 (ASC 360), “Property, Plant, and Equipment” which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360, at least on an annual basis. ASC 360 requires the impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. For the three months ended March 31, 2014 and year ended December 31, 2013 $0 and $158,292 was assessed and recorded as impairment on long-life assets.
	Intangible assets:
	Intangible assets consist of intellectual property and software acquired. At least annually, we evaluate purchased intangibles for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense. There was no impairment of intangible assets as of and for the three months ended March 31, 2014 and the year ended December 31, 2013, respectively.
	Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Patents		14-Sep
	Capitalized license costs		10
	Software		3
	Research and Development Expenses:
	Research and development costs are generally expensed as incurred. The Company’s research and development expenses consist of costs incurred for internal and external research and development.
	Share-Based Payments:
	In December 2004, the Financial Accounting Standards Board, or the FASB, issued the Statement of Financial Accounting Standards, or SFAS, No. 123(R), “Share-Based Payment”, which replaces SFAS No. 123 and supersedes APB Opinion No. 25. SFAS No. 123(R) is now included in the FASB’s ASC Topic 718, “Compensation – Stock Compensation.” Under SFAS No. 123(R), companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees or independent contractors are required to provide services. Share-based compensation arrangements include stock options and warrants, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, or SAB 107, which expresses views of the staff regarding the interaction between SFAS No. 123(R) and certain SEC rules and regulations and provides the staff’s views regarding the valuation of share-based payment arrangements for public companies. SFAS No. 123(R) permits public companies to adopt its requirements using one of two methods. On April 14, 2005, the SEC adopted a new rule amending the compliance dates for SFAS No. 123(R). Companies may elect to apply this statement either prospectively, or on a modified version of retrospective application under which financial statements for prior periods are adjusted on a basis consistent with the pro forma disclosures required for those periods under SFAS No. 123.
	The Company has fully adopted the provisions of FASB ASC 718 and related interpretations as provided by SAB 107. As such, compensation cost is measured on the date of grant as the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

PREPAID_EXPENSES

PREPAID EXPENSES	3 Months Ended
	Mar. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Prepaid Expenses [Text Block]	'
	NOTE 4: PREPAID EXPENSES
	Prepaid expenses consisted of the following:
		March 31,		December 31,
		2014		2013
	Prepaid stock purchase agreement service fee	$	576,961	$	651,961
	Prepaid marketing educational programs		230,000		-
	Prepaid hardware and software		31,551		131,204
	Prepaid insurance		125,714		112,517
	Retainer and security deposits		29,540		36,906
	Other		24,000		-
		$	1,017,766	$	932,588

PROPERTY_PLANT_AND_EQUIPMENT

PROPERTY, PLANT, AND EQUIPMENT	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	NOTE 5: PROPERTY, PLANT, AND EQUIPMENT
	Property, plant and equipment consisted of the following:
		March 31,		December 31,
		2014		2013
	Machinery and equipment	$	329,790	$	326,824
	Leasehold improvements		93,665		93,665
	Capitalized new product development costs		-		15,000
	Less: Accumulated depreciation		-135,221		-114,050
	Less: Allowance for loss on impairment		-158,292		-158,292
	Property, plant, and equipment, net	$	129,942	$	163,147
	Depreciation expense for the three months ended March 31, 2014 and 2013 was $21,171 and $4,869, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	NOTE 6: INTANGIBLE ASSETS
	Intangible assets consisted of the following:
		March 31,		December 31,
		2014		2013
	Patents	$	4,794,853	$	4,794,853
	Capitalized license costs		200,000		-
	Software		105,839		105,839
	Less: Accumulated amortization		-608,985		-505,059
		$	4,491,707	$	4,395,633
	Intangible assets amounted to $4,491,707 and $4,395,633 as of March 31, 2014 and December 31, 2013, respectively, and consisted of patents, capitalized license costs and software acquired. The acquired software mainly consisted of $58,000 in laboratory software and $31,500 in the newly developed Company website.  The amortization period for the purchased software is 3 years. Amortization expense related to software for the three months ended March 31, 2014 and 2013 was $8,761 and $4,678, respectively.
	Patents amounted to $4,794,853 as of March 31, 2014 and December 31, 2013, respectively, and mainly consisted of patents acquired from Acueity on September 30, 2012 in an asset purchase transaction. Patent assets are amortized based on their determined useful life, and tested annually for impairment. The amortization period was from 9 to 14 years. Amortization expense related to patents was $93,497 and $89,398 for the three months ended March 31, 2014 and 2013, respectively.
	Capitalized license costs consist of fees paid to A5 Genetics KFT, Corporation, pursuant to which the Company received the world-wide (other than the European Union) exclusive license to use the software in the NextCYTE test. Amortization expense related to license costs was $1,668 and $0 for the three months ended March 31, 2014 and 2013, respectively.
	Future estimated amortization expenses as of March 31, 2014 for the five succeeding years is as follows:
	As of December 31,	Amounts
	2014 (includes the remainder of the year)	$	313,525
	2015		412,212
	2016		404,951
	2017		393,982
	2018		393,982
	Thereafter		2,573,055
		$	4,491,707

PAYROLL_LIABILITIES

PAYROLL LIABILITIES	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	NOTE 7: PAYROLL LIABILITIES:
	Payroll liabilities consisted of the following:
		March 31,		December 31,
		2014		2013
	Accrued bonus payable	$	116,031	$	408,362
	Accrued payroll liabilities		67,003		48,232
	Accrued payroll tax liabilities		12,862		19,883
		$	195,896	$	476,477

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

'

Stockholders' Equity Note Disclosure [Text Block]

'

NOTE 8: STOCKHOLDERS’ EQUITY

The Company is authorized to issue a total of 85,000,000 shares of stock consisting of 75,000,000 shares of Common Stock, par value $0.001 per share, and 10,000,000 shares of Preferred Stock, par value $0.001 per share.

Reverse Stock-Split

On September 28, 2010, the Board of Directors approved a 1-for-2.26332 reverse share split for all issued and outstanding shares of Common Stock, with no change to the par value of the Common Stock.

Prior Issuances of Common Stock at Inception

On April 30, 2009 (inception), the Company issued 1,767,316 shares (or 4,000,000 shares prior to the reverse stock-split on September 28, 2010) to Ensisheim Partners LLC, a related party to the Company through common ownership, for cash in the amount of $24,000, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010); 1,325,487 shares (or 3,000,000 shares prior to the reverse stock-split on September 28, 2010) to Manistee Ventures LLC, a related party to the Company through common ownership, for cash in the amount of $18,000, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010); and 883,662 shares (or 2,000,000 shares prior to the reverse stock-split on September 28, 2010) to the Chairman, CEO and President of the Company at that time for cash in the amount of $12,000, or $0.014 per share (or $0.006 per share prior to the reverse stock-split on September 28, 2010).

Private Placements and Warrants

On April 28, May 31, June 10, and June 23, 2011, pursuant to Securities Purchase Agreements with various investors (the “Investors”), the Company issued 5,256,800 shares of the Company’s common stock and 5,256,800 warrants (the “Investor Warrants”), each of which entitles the investors to purchase the Company’s common stock at $1.25 per share, for aggregate gross proceeds of $6,571,000 (the “Private Placement”).

Placement Agent Fees

In connection with the Private Placement, the Company paid Dawson James Securities, Inc. (the “Placement Agent”), a cash fee equal to 10% of the gross proceeds from sale of the common stocks and warrants, plus a 3% non-accountable expense allowance, which resulted in a payment to the Placement Agent of an aggregate of $857,230 (the “Placement Agent Fee”). In addition, the Company entered into Warrant Agreements with the Placement Agent pursuant to which the Placement Agent received 788,520 warrants, each of which entitles the Placement Agent to purchase one share of the Company’s common stock at $1.60 per share, plus an additional 788,520 warrants (collectively with the warrants exercisable at $1.25 per share, the “Placement Agent Warrants”), each of which entitles the placement agent to purchase the Company’s common stock at $1.25 per share. The cash payment of the $857,230 Placement Agent Fee and the $495,876 aggregated initial fair value of the Placement Agent Warrants (see Fair Value Considerations below) were directly attributable to an actual offering and were charged through additional paid-in capital in accordance with the SEC Staff Accounting Bulletin (SAB) Topic 5A.

Warrants

The Warrants, including the Investor Warrants and the Placement Agent Warrants, are exercisable at any time commencing after June 23, 2011 which is the date that the Company completed a “significant private financing” under the terms of the Warrants (the “Initial Exercise Date”). The Warrants shall expire and no longer be exercisable on the fifth anniversary of the Initial Exercise Date (the “Expiration Date”). The Warrants may be exercised for cash or, at the option of the holder, may be exercised on a cashless basis; however if a registration statement is in effect for the resale of the common stock issuable upon exercise of the Warrants then the Warrants cannot be exercised on a cashless basis. As of March 31, 2014 such a registration statement was in effect and, therefore, the Warrants cannot be exercised on a cashless basis. There are no redemption features embodied in the Warrants and they have met the conditions provided in current accounting standards for equity classification.

Fair Value Considerations

The Company’s accounting for the issuance of Warrants to the Investors and the Placement Agent required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The Warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.

The Investor Warrants and the Placement Agent Warrants were initially valued at $1,808,025 or $0.34 per warrant, $228,712 or $0.29 per warrant, and $267,164 or $0.34 per warrant, respectively. The following tables reflect assumptions used to determine the fair value of the Warrants:

Fair

April-June 2011

December 2011

Value

Investor Warrants

Placement Agent

Placement

Hierarchy

Warrants

Agent

Level

Warrants

Indexed shares

5,256,800

788,520

788,520

Exercise price

$

1.6

$

1.6

$

1.25

Significant assumptions:

Stock price

3

$

0.906

$

0.906

$

0.906

Remaining term

3

6 years

6 years

6 years

Risk free rate

2

2.49

%

1.12

%

1.12

%

Expected volatility

3

53.55

%

54.21

%

54.21

%

Fair value hierarchy of the above assumptions can be categorized as follows:

-1

There were no Level 1 inputs.

-2

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

-3

Level 3 inputs include:

Stock price- The Company’s common stock was not publicly traded at the time the Warrants were issued. Therefore, the stock price was determined implicitly from an iterative process in order for the combined fair value of the common stock and the warrants to equal the amount of proceeds received in the Private Placement, based upon the assumption that the Private Placement was the result of an arm’s length transaction.

Remaining term- The Company does not have a history to develop the expected term for its Warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the Warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.

Asset Purchase and Warrants

On September 30, 2012, pursuant to the asset purchase agreement with Acueity, the Company issued 862,500 shares of common stock and 325,000 warrants (“Acueity Warrants”) to the shareholders of Acueity, each of which entitles the recipients to subscribe for and purchase from the Company one share of the Company’s common stock at $5.00 per share (the “Exercise Price”), subject to a six-month lock up agreement.

Warrants

The Acueity Warrants are exercisable at any time commencing after September 30, 2012 (the “Issuance Date”) and shall expire and no longer be exercisable on the fifth anniversary of the Issuance Date (the “Expiration Date”). The Company may at any time during the term of the Acueity Warrants reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company. The Acueity Warrants do not have a cashless exercise provision. There are no redemption features embodied in the Acueity Warrants and they have met the conditions provided in current accounting standards for equity classification.

Fair Value Considerations

The Company’s accounting for the issuance of the Acueity Warrants required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.

The Acueity Warrants were valued at $762,353 or $2.35 per warrant. The following tables reflect assumptions used to determine the fair value of the Warrants:

Fair

September 2012

Value

Hierarchy

Level

Acueity Warrants

Indexed shares

325,000

Exercise price

$

5

Significant assumptions:

Stock price

3

$

5

Remaining term

3

5 years

Risk free rate

2

0.62

%

Expected volatility

3

56.54

%

Fair value hierarchy of the above assumptions can be categorized as follows:

-1

There were no Level 1 inputs.

-2

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

-3

Level 3 inputs include:

Stock price- The Company’s common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).

Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.

2014 Public Offering of Common Stock and Warrants

On January 29, 2014, the Company closed a public offering of 5,834,234 units at the price of $2.40 per unit for the total gross proceed of approximately $14.0 million. Each unit consists of one share of common stock and a warrant to purchase 0.20 of a share of common stock (the “2014 Investor Warrants”). The 2014 Investor Warrants are exercisable at $3.00 per share and callable by the Company at $6.00 per share if certain conditions are met.

Placement Agent Fees

In connection with the 2014 Public Offering, the Company paid Dawson James Securities, Inc. (the “Placement Agent”), a cash fee equal to 7% of the gross proceeds from sale of the units, which resulted in a payment to the Placement Agent of an aggregate of $980,151 (the “Placement Agent Fee”). In addition, the Company entered into Warrant Agreements with the Placement Agent pursuant to which the Placement Agent received 175,027 warrants, or 3% of the aggregate number of shares sold in the offering (the “2014 Placement Agent Warrants” and together with the 2014 Investor Warrants, the “2014 Warrants”). Each 2014 Placement Agent Warrant entitles the Placement Agent to purchase one share of the Company’s common stock at $3.00 per share. The cash payment of the $980,151 2014 Placement Agent Fee and the $121,707 aggregated initial fair value of the 2014 Placement Agent Warrants (see Fair Value Considerations below) were directly attributable to an actual offering and were charged through additional paid-in capital in accordance with the SEC Staff Accounting Bulletin (SAB) Topic 5A.

Warrants

The 2014 Warrants are exercisable at any time commencing after January 29, 2014 (the “Initial Exercise Date”). Subject to the call right described above, the 2014 Warrants shall expire and no longer be exercisable on the fifth anniversary of the Initial Exercise Date on November 29, 2018 (the “Expiration Date”). The 2014 Warrants cannot be exercised on a cashless basis. There are no redemption features embodied in the 2014 Warrants and they have met the conditions provided in current accounting standards for equity classification.

Fair Value Consideration

The Company’s accounting for the issuance of the 2014 Warrants required the estimation of fair values of the financial instruments. The development of fair values of financial instruments requires the selection of appropriate methodologies and the estimation of often subjective assumptions. The Company selected the valuation techniques based upon consideration of the types of assumptions that market participants would likely consider in exchanging the financial instruments in market transactions. The 2014 Warrants were valued using a Black-Scholes-Merton Valuation Technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments.

The 2014 Investor Warrants and the 2014 Placement Agent Warrants were valued at $834,986 or $0.72 per warrant, and $121,707 or $0.70 per warrant, respectively. The following tables reflect assumptions used to determine the fair value of the 2014 Warrants:

Fair

January 29, 2014

Value

2014 Investor Warrants

Placement

Hierarchy

Agent

Level

Warrants

Indexed shares

1,166,849

175,027

Exercise price

$

3

$

3

Significant assumptions:

Stock price

1

$

2.5

$

2.47

Remaining term

3

5 years

5 years

Risk free rate

2

1.45

%

1.42

%

Expected volatility

3

37.96

%

37.95

%

Fair value hierarchy of the above assumptions can be categorized as follows:

-1

Level 1 inputs include:

Stock price- The Fair value of Company’s common was derived from the closing prices in NASDAQ Capital Market as of the issuance.

-2

Level 2 inputs include:

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

-3

Level 3 inputs include:

Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified five public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.

Outstanding Warrants

As of March 31, 2014, warrants to purchase 6,073,426 shares of common stock are outstanding including:

-1

4,292,050 warrants from the 2011 private placement (exercisable at $1.25 or $1.60),

-2

325,000 warrants issued in the Acueity transaction (exercisable at $5.00),

-3

1,166,849 warrants from the January 29, 2014 Public Offering (exercisable at $3.00), and

-4

242,027 warrants granted as placement agent fees for the Company’s offerings during 2013 and January 29, 2014 (exercisable from $2.12 to $12.43).

(5)

47,500 warrants granted to an outside consulting firm (exercisable at $4.24).

Stock Options and Incentive Plan

On September 28, 2010, the Board of Directors approved the adoption of the 2010 Stock Option and Incentive Plan, or the 2010 Plan, subject to stockholder approval, to provide for the grant of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. Awards of incentive options may be granted under the 2010 Plan until September 2020. No other awards may be granted under the 2010 Plan after the date that is 10 years from the date of stockholder approval. An aggregate of 1,000,000 shares (or 2,263,320 shares prior to the reverse stock-split on September 28, 2010) were initially reserved for issuance in connection with awards granted under the 2010 Plan, such number of shares to be subject to adjustment as provided in the plan and in any award agreements entered into by the Company under the plan, and upon the exercise or conversion of any awards granted under the plan. On January 1, 2012, 450,275 shares were added to the 2010 Plan and on January 1, 2013, 516,774 shares were added to the 2010 Plan, and on January 1, 2014, 742,973 shares were added to the 2010 plan as provided under the terms of the 2010 Plan.

The Company granted options to purchase 334,397 shares of common stock to employees and directors during the three months ended March 31, 2014.  During the quarter ended March 31, 2014, a new member of the Board of Directors was appointed and in connection with that appointment he earned the right to receive 22,728 shares of restricted stock under the 2010 Plan; however, these shares were not issued as of March 31, 2014. The Company issued no shares of common stocks in connection with the exercise of employee’s stock options during the three months ended March 31, 2014.  As of March 31, 2014, there are 897,617 options available for grant under the 2010 Plan.

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 9: INCOME TAXES
	The Company accounts for income taxes as outlined in ASC 740, “Income Taxes”, which was previously Statement of Financial Accounting Standards No. 109, “Accounting for Income Taxes” (“SFAS 109”). Under the asset and liability method of SFAS 109, deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
	As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No income tax liabilities existed as of March 31, 2014 and December 31, 2013 due to the Company’s continuing operating losses.

CONCENTRATION_OF_CREDIT_RISK

CONCENTRATION OF CREDIT RISK	3 Months Ended
	Mar. 31, 2014
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	NOTE 10: CONCENTRATION OF CREDIT RISK
	Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At March 31, 2014 and December 31, 2013, the Company had $16,340,951 and $6,092,161 in excess of the FDIC insured limit, respectively.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 11: COMMITMENTS AND CONTINGENCIES
	Lease Commitments
	On March 4, 2011, the Company entered into a commercial lease agreement with Sanders Properties, LLC for office space located in Seattle, WA. The lease provides for monthly rent of $1,100 and a security deposit of $1,500. The lease terms are from April 1, 2011 through March 31, 2014. On March 20, 2014, the Company entered into a new agreement with Sanders properties which extends the terms of the lease through March 31, 2015 with a monthly rent of $1,150.
	On December 9, 2011, the Company entered into another commercial lease agreement with Fred Hutchinson Research Center for lab and office space located in Seattle, WA. The lease provides for monthly rent of $16,395 for the period from February 24, 2012 to August 31, 2012, $19,923 for the period from September 1, 2012 to August 31, 2013, and $20,548 for the period from September 1, 2013 to November 29, 2014. The security deposit of $32,789 was paid in March 2012 and recorded as Security Deposit on the consolidated balance sheet as of December 31, 2012. In July 2013, the Company entered into an agreement with ARE LLC (Alexandria) to lease additional office spaces in our existing building under a separate lease agreement. The lease is from August 2013 through November 2014, and the gross rent is $ 4,800 per month. For the three months ended March 31, 2014, the Company incurred $65,605 of rent expense for the lease, which included leasing office management expenses.
	On March 24, 2014, the Company entered into another commercial lease agreement with ARE LLC (Alexandria) for the Company’s laboratory space  which extends the term of the existing lease with Fred Hutchison Research Center, which expires in November 2014, through November 30, 2016. The lease provides for monthly rent payments of $22,736 from December 2014 through November 2015 and $23,258 from December 2015 through November 2016. As of March 31, 2014, the Company incurred and recorded security deposits of $25,000.
	The future minimum lease payments due subsequent to March 31, 2014 under all non-cancelable operating leases for the next five years are as follows:
	As of December 31,	Amount
	2014 (remainder of the year)	$	247,939
	2015		276,805
	2016		255,845
	2017		-
	2018		-
	Thereafter		-
	Total minimum lease payments	$	780,589
	Affymetrix Purchase Commitment
	In September 2013, the Company entered into an “OwnerChip Program Agreement” with Affymetrix, Inc, a manufacturer of GeneChip Systems, where Affymetrix has agreed to loan a GeneChip System 3000Dx v.2 (“instrument”) to us if we purchase and take delivery of a minimum thirty GeneChip Human Genme U133 Plus 2.0 (30-pack) arrays at $21,590 per 30 pack for the next three years for a total purchase obligation of $647,700 with a minimum purchase of ten 30-pack arrays per contract year.  At the end of the three year contract, upon fulfillment of the purchase commitment, the instrument title and ownership transfer to Atossa at no additional cost.   In addition to the GeneChip Human Genme, we must purchase a two year service contract for $51,600 to cover maintenance of the instrument during the contract period.   We placed an initial order for four 30-pack arrays during 2013 for $94,723.  We are obligated to purchase 26 additional arrays during the next three year contract term.
	A5 Software Development Commitment
	On June 10, 2013 the Company entered into an irrevocable license and service agreement with A5 Genetics KFT, Corporation, pursuant to which the Company received the world-wide (other than the European Union) exclusive license to the software used in the NextCYTE test.  The Company has the right to prosecute patents related to this software, two of which the Company has filed in the United States.  The patent applications have been assigned to us.  The Company paid a one-time fee of $100,000 to A5 Genetics in 2013 and in March 2014 the Company completed software validation and paid an additional $100,000 to A5 Genetics.  The Company is obligated to pay up to an additional $1.2 million to A5 Genetics upon the achievement of future milestones.  The Company must also pay a royalty of $50 for each NextCYTE Test performed and $65 as a service fee for each NextCYTE Test performed.  The agreement terminates on the later of the ten year anniversary of the agreement or the expiration of the latest to expire patent covering the software.
	Contingencies
	On June 30, 2011, Robert Kelly, the Company’s former President, filed a counterclaim against the Company in an arbitration proceeding, alleging breach of contract in connection with the termination of a consulting agreement between Mr. Kelly (dba Pitslayer LLC) and the Company that was entered into in July 2010 in connection with his resignation from the Company as President and a director. The consulting agreement was terminated by the Company in September 2010. Mr. Kelly seeks $450,000 in compensatory damages, which is the amount he claims would have been earned had the consulting agreement been fulfilled to completion.
	On December 11, 2012, Mr. Kelly filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the termination of Mr. Kelly’s consulting contract and the rescission of shares issued to him in July 2010 in connection with his resignation from the Company as President and a director. The specific amount of damages sought is to be proven at trial and is not specified. On July 8, 2013, the court granted the Company’s motion to compel arbitration of these claims and therefore this action was stayed pending resolution of the arbitration of the claims; however, Mr. Kelly has not initiated arbitration of those claims.
	On February 26, 2013, Mr. Victor Cononi filed a complaint in the United States District Court, Western Division of Washington seeking compensatory damages, interest and attorneys’ fees related to the rescission of shares issued to him in July 2010 in connection with Mr. Kelly’s resignation from the Company as President and a director. Mr. Cononi is the father of Mr. Kelly’s paramour. The specific amount of damages sought is to be proven at trial and is not specified. In August 2013, the court granted the Company’s motion to compel arbitration of these claims and therefore this action was stayed pending resolution of the arbitration of the claims; however, Mr. Cononi has not initiated arbitration of those claims.
	A hearing in the arbitration has been held in abeyance to accommodate other third party civil and federal criminal proceedings alleging securities and wire fraud that have been brought against Mr. Kelly with respect to his prior employment and predating his service with the Company. On March 11, 2014 a press release was issued by the FBI stating that Mr. Kelly had pled guilty in Manhattan federal court to securities and wire fraud charges related to his employment as CEO of Wwebnet. Mr. Kelly also agreed to forfeit $2,111,600 and, separately, pay $2,111,600 in restitution. The sentencing hearing is scheduled for July 17, 2014.
	The Company is reasonably confident in its defenses to Mr. Kelly’s and Mr. Cononi’s claims. Consequently, no provision or liability has been recorded for these claims as of March 31, 2014. However, it is at least reasonably possible that the Company’s estimate of liability may change in the near term. Any payments by reason of an adverse determination in this matter will be charged to earnings in the period of determination.
	On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al., No. 2:13-cv-01836-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering.  The complaint alleges that all defendants violated Sections 11 and 12(a)(2), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10(b) and 20A of the Exchange Act and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device.   This action seeks, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount.
	On February 14, 2014, the Court appointed plaintiffs Miko Levi, Bandar Almosa and Gregory Harrison (collectively, the “Levi Group”) as lead plaintiffs, and approved their selection of co-lead counsel and liaison counsel.  The Court also amended the caption of the case to read In re Atossa Genetics, Inc. Securities Litigation. No. 2:13-cv-01836-RSM.  An amended complaint was filed on April 15, 2014.
	We believe this lawsuit is without merit and plan to defend ourselves vigorously; however, failure by us to obtain a favorable resolution of the claims set forth in the complaint could have a material adverse effect on our business, results of operations and financial condition.  Currently, the amount of such material adverse effect cannot be reasonably estimated, and no provision or liability has been recorded for these claims as of March 31, 2014.  The costs associated with defending and resolving the lawsuit and ultimate outcome cannot be predicted.  These matters are subject to inherent uncertainties and the actual cost, as well as the distraction from the conduct of our business, will depend upon many unknown factors and management’s view of these may change in the future.
	FDA Warning Letter
	On February 21, 2013, the Company received a Warning Letter (“Warning Letter”) from the FDA regarding its Mammary Aspirate Specimen Cytology Test (MASCT) System and MASCT System Collection Test (together, the “System”).  The Warning Letter arises from certain FDA findings during a July 2012 inspection, to which the Company responded in August 2012, explaining why the Company believed it was in compliance with applicable regulations and/or was implementing changes responsive to the findings of the FDA inspection.  The FDA alleges in the Warning Letter that following 510(k) clearance of the MASCT System, the Company changed the System in a manner that requires submission of an additional 510(k) notification to the FDA. Specifically, the FDA stated that the Instructions For Use (IFU) in the original 510(k) submission stated that the user must “Wash the collection membrane with fixative solution into the collection vial…” while the current IFU states “…apply one spray of Saccomanno’s Fixative to the collection membrane…” and that “this change fixes the NAF specimen to the filter paper rather than washing it into a collection vial.” At the time that the changes were made the Company determined and documented that the change could not significantly affect the safety or effectiveness of the MASCT System, and thus, that a new 510(k) was not required in accordance with the FDA’s guidance document entitled, “Deciding When to Submit a 510(k) for a Change to an Existing Device.” The Warning Letter also identified certain issues with respect to the Company’s marketing of the System and the Company’s compliance with FDA Good Manufacturing Practices (cGMP) regulations, among other matters. The Company responded to the Warning Letter on March 13, 2013, and identified the corrective actions that had been made, or were otherwise underway The Company also filed a new 510(k) application for the MASCT System which was withdrawn in August 2013 after receiving feedback from the FDA.
	On October 4, 2013, the Company initiated a voluntary recall of the system to address FDA’s concerns regarding the modifications identified in the Warning Letter. As a result of this recall, this product is currently not being marketed or distributed in the U.S.  The Company submitted a new premarket notification or 510(k) application for submission to the FDA on December 23, 2013 that covers the collection, preparation, and processing of NAF specimens at our laboratory and includes the spray method of fixing specimens to the collection membrane. We received a request from the FDA on February 28, 2014 to submit additional information in support of the application. We have until August 20, 2014 to respond to the FDA. We cannot market or distribute the ForeCYTE Breast Aspirator within United States until we receive clearance for this device form FDA.
	On March 14, 2014, the FDA completed a follow up inspection at our Seattle facility.  A Form 483 was provided to us at the conclusion of the inspection. In the FDA's most recent Form 483, five inspectional observations were identified regarding our quality management system.  The FDA inspector also orally identified five additional discussion points related to our product labeling prior to the recall of the MASCT System; sufficiency of the content of our pending 510(k) submission for the ForeCYTE Breast Aspirator; and other compliance issues. On March 26, 2014, we submitted a response to the FDA, which included our proposed corrective actions to address the FDA's observations and discussion points. Whether the FDA will accept our response is uncertain, particularly in light of the similar nature of certain of the current inspectional observations to previous inspectional observations. If the FDA does not agree with our proposed corrective actions, or accepts them but finds that we have not implemented them adequately, or if we otherwise are found to be out of compliance with applicable regulatory requirements at a later date, the FDA could initiate an enforcement action including additional warning letters, fines and penalties.  The FDA also may not clear our pending 510(k) for the ForeCYTE Breast Aspirator or our other devices and services under development.  Any of the foregoing would have a material adverse effect on our business.
	As of March 31, 2014, the Company has $96,201 in contingent liability and has incurred $339,042 in actual expenses related to the costs of the recall, including the estimated costs of pursuing the additional 510(k) clearance.  The recall and 510(k) process may take longer than expected and we may incur costs that we have not anticipated.  Accordingly, the actual amount of the loss contingency may be higher than we currently expect.

STOCK_BASED_COMPENSATION

STOCK BASED COMPENSATION	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 12: STOCK BASED COMPENSATION
	In accordance with the guidance provided in ASC Topic 718, Stock Compensation (formerly SFAS 123R), the compensation costs associated with the options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized a compensation expense of $230,181 and $274,511 for the three months ended March 31, 2014 and 2013, respectively.
	The Company estimated the fair value of these options using the Black-Scholes-Merton option pricing model based on the following weighted-average assumptions:
	Year Ended December 2013		Employees		Employees &		Directors		CEO &
					Officers				CSO
	Date of Grant		January -		January - June 2013		May & October		Mar-13
			Dec-13				2013
	Fair value of common stock on date of grant (A)		$2.05 - $5.19		$4.11 - $4.58		$2.04 - $6.59		$	6.57
	Exercise price of the options		$2.05 - $5.19		$4.11 - $4.58		$2.04 - $6.59		$	6.57
	Expected life of the options (years)		6.09 - 6.11		5.00 – 6.11		5.00 – 5.31			5
	Dividend yield		0	%	0	%	0	%		0	%
	Expected volatility		40.73 – 41.81	%	40.96 - 41.05	%	41.06-41.53	%		47.09	%
	Risk-free interest rate		1.73 -1.97	%	1.03-1.36	%	0.73 - 1.49	%		1.13	%
	Expected forfeiture per year (%)		10	%	10	%	10	%		0	%
	Weighted average fair value of the options per unit		$0.878 - $2.18		$1.69 - $1.89		$0.790 - $2.49		$	2.7
	Three Months Ended March 2014		Employees				Officers				Directors
	Date of Grant		January 8, 2014				January 8, 2014				March 1, 2014
	Fair value of common stock on date of grant(A)		$	2.2			$	2.2			$	2.2
	Exercise price of the options		$	2.2			$	2.2			$	2.2
	Expected life of the options (years)			6.06				6.06				5.09
	Dividend yield			0	%			0	%			0	%
	Expected volatility			41.70- 41.72	%			41.7	%			38.68	%
	Risk-free interest rate			2.11	%			2.11	%			1.53	%
	Expected forfeiture per year (%)			10	%			10	%			10	%
	Weighted average fair value of the options per unit		$	0.95			$	0.95			$	0.8
		(A)	The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.
	Fair value hierarchy of the above assumptions can be categorized as follows:
		-1	Level 1 inputs include:
	Stock price- The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.
		-2	Level 2 inputs include:
	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the options.
		-3	Level 3 inputs include:
	Expected lives- The expected lives of options granted were derived from the output of the option valuation model and represented the period of time that options granted are expected to be outstanding.
	Expected forfeitures per year- The expected forfeitures are estimated at the dates of grant and will be revised in subsequent periods pursuant to actual forfeitures, if significantly different from the previous estimates.
	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result,  as required by ASC 718-10-30, the Company has accounted for the options using the calculated value method. The Company identified five to seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.
	The estimates of fair value from the model are theoretical values of stock options and changes in the assumptions used in the model could result in materially different fair value estimates. The actual value of the stock options will depend on the market value of the Company’s common stock when the stock options are exercised.
	Options issued and outstanding as of March 31, 2014 and their activities during the three months then ended are as follows:
			Number of			Weighted-			Weighted-
			Underlying			Average			Average
						Exercise			Contractual
						Price Per			Life
									Remaining
									in
			Shares			Share			Years			Aggregate Intrinsic Value
	Outstanding as of January 1, 2014			2,282,719		$	4.43
	Granted			311,669		$	2.2
	Expired			-		$	-
	Forfeited			-61,221		$	4.7
	Exercised			-		$	-
	Outstanding as of March 31, 2014			2,533,167		$	4.15			7.86		$	107,800
	Exercisable as of March 31, 2014			1,253,137		$	4.47			6.52		$	107,800
	Vested and expected to vest (1)			2,355,778		$	4.18			7.76		$	107,800
	(1) vested shares and unvested shares after a forfeiture rate is applied.
	Issuance of Restricted Common Stock for Director’s Compensation
	On October 10, 2013, the Company issued 24,510 shares of restricted stock with a grant date value of $50,000 or $2.04 per share to a new board member. The restriction will be removed as the shares vest quarterly for a proportional number of granted shares over the first year of service on the board, and the grant date value of such shares will be expensed in the quarter the restriction is removed.
	On March 1, 2014, the Company agreed to issue 22,728 shares of restricted stock with a grant date value of $50,000 or $2.20 per share to a new board member; however these shares have not been issued as of March 31, 2014. The restriction will be removed as shares vest quarterly for a proportional number of granted shares over the first year of service on the board, and the grant date value of such shares will be expensed in the quarter the restriction is removed.
	For the three months ended March 31, 2014, $230,181 was recorded as stock compensation expenses, including $16,611 for restricted stock.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 13: SUBSEQUENT EVENTS
	Management has evaluated subsequent events through May 14, 2014, the date which the consolidated financial statements were available to be issued.  All subsequent events requiring recognition as of March 31, 2014 have been incorporated into these consolidated financial statements, and besides the disclosures herein, there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events”.
	On May 6, 2014, the Board of Directors of the Company approved the following changes to the compensation arrangements of the Company’s named executive officers for fiscal year 2014:
	Name	Title	Annual base		Annual bonus potential as			Stock
			salary		a % of base salary			option grant
	Steven C. Quay,	Chief Executive Officer and	$	500,000		50	%		250,000
	Ph.D., M.D.	President
	Kyle Guse, CPA, J.D.	Chief Financial Officer, General Counsel and Secretary	$	350,000		45	%		200,000
	Shu-Chih Chen, Ph.D.	Chief Scientific Officer and Director of Human Resources	$	350,000		40	%		125,000
	The stock options were granted under the Company’s 2010 Stock Option and Incentive Plan. The options have an exercise price of $1.22, which is the fair market value on the date of grant, and vest quarterly over four years so long as the executive remains employed with the Company. The options are otherwise subject to the terms and conditions of the employment agreements with the executives.
	In addition to the foregoing named executive officers, certain other senior officers received salary adjustments on May 6, 2014 for the 2014 fiscal year totaling $143,438 for the quarter ended March 31, 2014.  The estimated expense of those salary adjustments has been accrued as of March 31, 2014.
	On May 6, 2014, options to purchase a total of 150,000 shares of common stock were also granted under the 2010 plan to non-employee directors and certain senior officers. The options have an exercise price of $1.22 which was the fair market value on the date of grant.  the options granted to non- employee directors vest quarterly over one year and options granted to the senior officers vest quarterly over four years. As of the date of filing this report, management was still in the process of determining the fair value of the options as described above, in accordance with FASB ASC Topic 718.

SUMMARY_OF_ACCOUNTING_POLICIES1

SUMMARY OF ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation:
	The accompanying consolidated financial statements include the financial statements of Atossa Genetics Inc. and its wholly-owned subsidiary NRLBH. All significant intercompany account balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements:
	The Company has adopted all recently issued accounting pronouncements that management believes to be applicable to the Company. The adoption of these accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition:
	Overview
	The Company recognizes product and service revenue in accordance with GAAP when the following overall fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or the service has been performed, (iii) the Company’s price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured.
	Product Revenue
	The Company recognizes revenue for sales of the MASCT kits and devices on an accrual basis for sales to distributors when the above four criteria are met. For sales of MASCT kits and devices directly to physicians, the revenue is typically recognized upon receipt of cash as the Company has an insufficient sales history on which to determine the collectability. Shipping documents and the completion of any customer acceptance requirements, when applicable, will be used to verify product delivery. The Company will assess whether a price is fixed or determinable based upon the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. For sales directly to physicians, once a history of sales and collectability has been established, the Company will recognize revenue on an accrual basis with an offsetting reserve for doubtful accounts based on the history during the initial sales period.
	Service Revenue
	The Company records revenue for diagnostic testing on an accrual basis at the Medicare allowed and invoiced amount. Amounts invoiced above the Medicare amount, namely non-Medicare, are not recognized on an accrual basis and instead are recognized on a cash basis as received. Diagnostic testing revenue at the Medicare rate is recognized upon completion of the test, communication of results to the patient’s physician, and when collectability is reasonably assured. Customer purchase orders and/or contracts are generally used to determine the existence of an arrangement. Once the Company has historical sales and can determine the proper amount to recognize as uncollectible, it will then begin to recognize the entire amount, both Medicare and non-Medicare billing on an accrual basis, with an offsetting allowance for doubtful accounts recorded based on history.
Cost of Sales, Policy [Policy Text Block]	'
	Cost of Revenue:
	Cost of revenue consists of cost of diagnostic testing services and cost of product sales. Cost of diagnostic testing services primarily includes direct cost of material, direct labor, equipment, and shipping to process the patient samples (including pathology, quality control analysis, and shipping charges to transport tissue sample) in our laboratory. Costs associated with performing the Company's tests are recorded as tests are processed. Costs recorded for tissue sample processing and shipping charges represent the cost of all the tests processed during the period regardless of whether revenue was recognized with respect to that test. Cost of product sales primarily includes manufacturing cost of our MASCT System for sales to distributors, which is recorded upon transfer of ownership of the goods.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents:
	Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates:
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	'
	Accounts Receivable:
	Accounts receivable are recorded at net realizable value consisting of the carrying amount less allowance for doubtful accounts, as needed. The Company assesses the collectability of accounts receivable based primarily upon the creditworthiness of the customer as determined by credit checks and analysis, as well as the customer’s payment history. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company’s allowance for doubtful accounts as of March 31, 2014 and December 31, 2013 was $382,721 and $354,861, respectively.
Inventory, Policy [Policy Text Block]	'
	Inventories:
	The Company’s inventories are stated at lower of cost or market. Cost is determined on a moving-average basis. Costs of inventories include purchase and related costs incurred in delivering the products to their present location and condition. Market value is determined by reference to selling prices after the balance sheet date or to management’s estimates based on prevailing market conditions. Inherent in the lower of cost or market calculation are several significant judgments based on a review of the aging of the inventory, inventory movement of products, economic conditions, and replacement costs. Management periodically evaluates the composition of its inventories at least quarterly to identify slow-moving and obsolete inventories to determine if any valuation allowance is required. During the course of our recall commenced in October 2013, we have recalled a substantial number of MASCT Systems. Based on management’s assessment of those devices and the pending FDA clearance, management decided to establish 100% allowance for valuation reserve on all MASCT Systems, and recorded $149,946 of losses on obsolete inventory for the year ended December 31, 2013. During March 31, 2014, management identified no additional slow moving or obsolete inventory. The Company outsources product manufacturing to outside manufacturer contactors.  The ownership of the goods transfers from the manufacturer to the Company’s customer at the time the products are shipped to the customers. As of March 31, 2014 and December 31, 2013, inventories amounted to $0 after netting of the above valuation allowance.
	The Company provides, either directly or through distributors, the NAF specimen collection kits to doctors with our MASCT System for doctors to collect specimens that are returned to the NRLBH or other laboratories for diagnostic analysis. These collection kits are considered part of the MASCT System. The Company’s direct sales personnel distributes the kits directly to physicians free of charge, or by offering a rebate to physicians. The Company has not intended to deem the kits as a primary product line due to their nominal cost and value per unit. As a result, the kits are immediately expensed and recorded as selling expense upon purchasing of the kits.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property, plant, and equipment:
	Property, plant and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property, plant and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.
	Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Machinery and equipment		5
	Leasehold improvements		2.083
	The Company applies the provisions of FASB ASC Topic 360 (ASC 360), “Property, Plant, and Equipment” which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance with ASC 360, at least on an annual basis. ASC 360 requires the impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. For the three months ended March 31, 2014 and year ended December 31, 2013 $0 and $158,292 was assessed and recorded as impairment on long-life assets.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	'
	Intangible assets:
	Intangible assets consist of intellectual property and software acquired. At least annually, we evaluate purchased intangibles for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Estimating future cash flows related to an intangible asset involves significant estimates and assumptions. If our assumptions are not correct, there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense. There was no impairment of intangible assets as of and for the three months ended March 31, 2014 and the year ended December 31, 2013, respectively.
	Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Patents		14-Sep
	Capitalized license costs		10
	Software		3
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Expenses:
	Research and development costs are generally expensed as incurred. The Company’s research and development expenses consist of costs incurred for internal and external research and development.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-Based Payments:
	In December 2004, the Financial Accounting Standards Board, or the FASB, issued the Statement of Financial Accounting Standards, or SFAS, No. 123(R), “Share-Based Payment”, which replaces SFAS No. 123 and supersedes APB Opinion No. 25. SFAS No. 123(R) is now included in the FASB’s ASC Topic 718, “Compensation – Stock Compensation.” Under SFAS No. 123(R), companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees or independent contractors are required to provide services. Share-based compensation arrangements include stock options and warrants, restricted share plans, performance-based awards, share appreciation rights and employee share purchase plans. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, or SAB 107, which expresses views of the staff regarding the interaction between SFAS No. 123(R) and certain SEC rules and regulations and provides the staff’s views regarding the valuation of share-based payment arrangements for public companies. SFAS No. 123(R) permits public companies to adopt its requirements using one of two methods. On April 14, 2005, the SEC adopted a new rule amending the compliance dates for SFAS No. 123(R). Companies may elect to apply this statement either prospectively, or on a modified version of retrospective application under which financial statements for prior periods are adjusted on a basis consistent with the pro forma disclosures required for those periods under SFAS No. 123.
	The Company has fully adopted the provisions of FASB ASC 718 and related interpretations as provided by SAB 107. As such, compensation cost is measured on the date of grant as the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.

SUMMARY_OF_ACCOUNTING_POLICIES2

SUMMARY OF ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Property, Plant and Equipment, Useful Life [Table Text Block]	'
	Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Machinery and equipment		5
	Leasehold improvements		2.083
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:
		Useful Life
		(in years)
	Patents		14-Sep
	Capitalized license costs		10
	Software		3

PREPAID_EXPENSES_Tables

PREPAID EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	'
	Prepaid expenses consisted of the following:
		March 31,		December 31,
		2014		2013
	Prepaid stock purchase agreement service fee	$	576,961	$	651,961
	Prepaid marketing educational programs		230,000		-
	Prepaid hardware and software		31,551		131,204
	Prepaid insurance		125,714		112,517
	Retainer and security deposits		29,540		36,906
	Other		24,000		-
		$	1,017,766	$	932,588

PROPERTY_PLANT_AND_EQUIPMENT_T

PROPERTY, PLANT, AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property, plant and equipment consisted of the following:
		March 31,		December 31,
		2014		2013
	Machinery and equipment	$	329,790	$	326,824
	Leasehold improvements		93,665		93,665
	Capitalized new product development costs		-		15,000
	Less: Accumulated depreciation		-135,221		-114,050
	Less: Allowance for loss on impairment		-158,292		-158,292
	Property, plant, and equipment, net	$	129,942	$	163,147

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets and Goodwill [Table Text Block]	'
	Intangible assets consisted of the following:
		March 31,		December 31,
		2014		2013
	Patents	$	4,794,853	$	4,794,853
	Capitalized license costs		200,000		-
	Software		105,839		105,839
	Less: Accumulated amortization		-608,985		-505,059
		$	4,491,707	$	4,395,633
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Future estimated amortization expenses as of March 31, 2014 for the five succeeding years is as follows:
	As of December 31,	Amounts
	2014 (includes the remainder of the year)	$	313,525
	2015		412,212
	2016		404,951
	2017		393,982
	2018		393,982
	Thereafter		2,573,055
		$	4,491,707

PAYROLL_LIABILITIES_Tables

PAYROLL LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Payroll liabilities consisted of the following:
		March 31,		December 31,
		2014		2013
	Accrued bonus payable	$	116,031	$	408,362
	Accrued payroll liabilities		67,003		48,232
	Accrued payroll tax liabilities		12,862		19,883
		$	195,896	$	476,477

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2014
Investor, Placement Agent1 and Placement Agent2 Warrants [Member]	'
Stockholders' Equity Note [Abstract]	'
Schedule of Fair Value of Warrants [Table Text Block]	'
	The following tables reflect assumptions used to determine the fair value of the Warrants:
			Fair		April-June 2011			December 2011
			Value		Investor Warrants			Placement Agent			Placement
			Hierarchy					Warrants			Agent
			Level								Warrants
	Indexed shares					5,256,800			788,520			788,520
	Exercise price				$	1.6		$	1.6		$	1.25
	Significant assumptions:
	Stock price			3	$	0.906		$	0.906		$	0.906
	Remaining term			3		6 years			6 years			6 years
	Risk free rate			2		2.49	%		1.12	%		1.12	%
	Expected volatility			3		53.55	%		54.21	%		54.21	%
	Fair value hierarchy of the above assumptions can be categorized as follows:
		-1	There were no Level 1 inputs.
		-2	Level 2 inputs include:
	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.
		-3	Level 3 inputs include:
	Stock price- The Company’s common stock was not publicly traded at the time the Warrants were issued. Therefore, the stock price was determined implicitly from an iterative process in order for the combined fair value of the common stock and the warrants to equal the amount of proceeds received in the Private Placement, based upon the assumption that the Private Placement was the result of an arm’s length transaction.
	Remaining term- The Company does not have a history to develop the expected term for its Warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the Warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.
Acueity Warrants [Member]	'
Stockholders' Equity Note [Abstract]	'
Schedule of Fair Value of Warrants [Table Text Block]	'
	The following tables reflect assumptions used to determine the fair value of the Warrants:
			Fair		September 2012
			Value
			Hierarchy
			Level		Acueity Warrants
	Indexed shares					325,000
	Exercise price				$	5
	Significant assumptions:
	Stock price			3	$	5
	Remaining term			3		5 years
	Risk free rate			2		0.62	%
	Expected volatility			3		56.54	%
	Fair value hierarchy of the above assumptions can be categorized as follows:
	-1	There were no Level 1 inputs.
	-2	Level 2 inputs include:
	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.
	-3	Level 3 inputs include:
	Stock price- The Company’s common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).
	Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.
Warrants 2014 and Placement Agent Warrants [Member]	'
Stockholders' Equity Note [Abstract]	'
Schedule of Fair Value of Warrants [Table Text Block]	'
	The following tables reflect assumptions used to determine the fair value of the 2014 Warrants:
			Fair		January 29, 2014
			Value		2014 Investor Warrants			Placement
			Hierarchy					Agent
			Level					Warrants
	Indexed shares					1,166,849			175,027
	Exercise price				$	3		$	3
	Significant assumptions:
	Stock price			1	$	2.5		$	2.47
	Remaining term			3		5 years			5 years
	Risk free rate			2		1.45	%		1.42	%
	Expected volatility			3		37.96	%		37.95	%
	Fair value hierarchy of the above assumptions can be categorized as follows:
		-1	Level 1 inputs include:
	Stock price- The Fair value of Company’s common was derived from the closing prices in NASDAQ Capital Market as of the issuance.
		-2	Level 2 inputs include:
	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.
		-3	Level 3 inputs include:
	Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified five public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entities’ share prices in calculating the expected volatility appropriate to the Company.

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Operating Leases of Lessee Disclosure [Table Text Block]	'
	The future minimum lease payments due subsequent to March 31, 2014 under all non-cancelable operating leases for the next five years are as follows:
	As of December 31,	Amount
	2014 (remainder of the year)	$	247,939
	2015		276,805
	2016		255,845
	2017		-
	2018		-
	Thereafter		-
	Total minimum lease payments	$	780,589

STOCK_BASED_COMPENSATION_Table

STOCK BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The Company estimated the fair value of these options using the Black-Scholes-Merton option pricing model based on the following weighted-average assumptions:
	Year Ended December 2013	Employees		Employees &		Directors		CEO &
				Officers				CSO
	Date of Grant	January -		January - June 2013		May & October		Mar-13
		Dec-13				2013
	Fair value of common stock on date of grant (A)	$2.05 - $5.19		$4.11 - $4.58		$2.04 - $6.59		$	6.57
	Exercise price of the options	$2.05 - $5.19		$4.11 - $4.58		$2.04 - $6.59		$	6.57
	Expected life of the options (years)	6.09 - 6.11		5.00 – 6.11		5.00 – 5.31			5
	Dividend yield	0	%	0	%	0	%		0	%
	Expected volatility	40.73 – 41.81	%	40.96 - 41.05	%	41.06-41.53	%		47.09	%
	Risk-free interest rate	1.73 -1.97	%	1.03-1.36	%	0.73 - 1.49	%		1.13	%
	Expected forfeiture per year (%)	10	%	10	%	10	%		0	%
	Weighted average fair value of the options per unit	$0.878 - $2.18		$1.69 - $1.89		$0.790 - $2.49		$	2.7
	Three Months Ended March 2014	Employees				Officers				Directors
	Date of Grant	January 8, 2014				January 8, 2014				March 1, 2014
	Fair value of common stock on date of grant(A)	$	2.2			$	2.2			$	2.2
	Exercise price of the options	$	2.2			$	2.2			$	2.2
	Expected life of the options (years)		6.06				6.06				5.09
	Dividend yield		0	%			0	%			0	%
	Expected volatility		41.70- 41.72	%			41.7	%			38.68	%
	Risk-free interest rate		2.11	%			2.11	%			1.53	%
	Expected forfeiture per year (%)		10	%			10	%			10	%
	Weighted average fair value of the options per unit	$	0.95			$	0.95			$	0.8
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	Options issued and outstanding as of March 31, 2014 and their activities during the three months then ended are as follows:
		Number of			Weighted-			Weighted-
		Underlying			Average			Average
					Exercise			Contractual
					Price Per			Life
								Remaining
								in
		Shares			Share			Years			Aggregate Intrinsic Value
	Outstanding as of January 1, 2014		2,282,719		$	4.43
	Granted		311,669		$	2.2
	Expired		-		$	-
	Forfeited		-61,221		$	4.7
	Exercised		-		$	-
	Outstanding as of March 31, 2014		2,533,167		$	4.15			7.86		$	107,800
	Exercisable as of March 31, 2014		1,253,137		$	4.47			6.52		$	107,800
	Vested and expected to vest (1)		2,355,778		$	4.18			7.76		$	107,800
	(1) vested shares and unvested shares after a forfeiture rate is applied.

SUBSEQUENT_EVENTS_Tables

SUBSEQUENT EVENTS (Tables)	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Schedule of changes to the compensation arrangement [Table Text Block]	'
	Board of Directors of the Company approved the following changes to the compensation arrangements of the Company’s named executive officers for fiscal year 2014:
	Name	Title	Annual base		Annual bonus potential as			Stock
			salary		a % of base salary			option grant
	Steven C. Quay,	Chief Executive Officer and	$	500,000		50	%		250,000
	Ph.D., M.D.	President
	Kyle Guse, CPA, J.D.	Chief Financial Officer, General Counsel and Secretary	$	350,000		45	%		200,000
	Shu-Chih Chen, Ph.D.	Chief Scientific Officer and Director of Human Resources	$	350,000		40	%		125,000

NATURE_OF_OPERATIONS_Details_T

NATURE OF OPERATIONS (Details Textual) (USD $)	3 Months Ended		9 Months Ended	59 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Sep. 30, 2012	Mar. 31, 2014
Nature Of Operations [Line Items]	'	'	'	'
Revenue, Net	$24,124	$182,670	'	$1,140,024
Cash Acquired from Acquisition	'	'	$400,000	'

SUMMARY_OF_ACCOUNTING_POLICIES3

SUMMARY OF ACCOUNTING POLICIES (Details)	3 Months Ended
	Mar. 31, 2014
Machinery and Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment, Useful Life (in years)	'5 years
Leasehold Improvements [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment, Useful Life (in years)	'2 years 30 days

SUMMARY_OF_ACCOUNTING_POLICIES4

SUMMARY OF ACCOUNTING POLICIES (Details 1)	3 Months Ended
	Mar. 31, 2014
Patents [Member] | Minimum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Finite-Lived Intangible Asset, Useful Life (in years)	'9 years
Patents [Member] | Maximum [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Finite-Lived Intangible Asset, Useful Life (in years)	'14 years
Capitalized license costs [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Finite-Lived Intangible Asset, Useful Life (in years)	'10 years
Computer Software, Intangible Asset [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Finite-Lived Intangible Asset, Useful Life (in years)	'3 years

SUMMARY_OF_ACCOUNTING_POLICIES5

SUMMARY OF ACCOUNTING POLICIES (Details Textual) (USD $)	3 Months Ended		12 Months Ended	59 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014
Accounting Policies [Line Items]	'	'	'	'
Allowance for Doubtful Accounts Receivable	$382,721	'	$354,861	$382,721
Loss On Reduction Of Inventory To The Lower Of Cost Or Market	0	0	149,946	271,856
Inventory, Net, Total	0	'	0	0
Impairment of Long-Lived Assets Held-for-use	$0	'	$158,292	$158,292

PREPAID_EXPENSES_Details

PREPAID EXPENSES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets [Line Items]	'	'
Prepaid stock purchase agreement service fee	$576,961	$651,961
Prepaid marketing educational programs	230,000	0
Prepaid hardware and software	31,551	131,204
Prepaid insurance	125,714	112,517
Retainer and security deposits	29,540	36,906
Other	24,000	0
Prepaid expense	$1,017,766	$932,588

PROPERTY_PLANT_AND_EQUIPMENT_D

PROPERTY, PLANT, AND EQUIPMENT (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Machinery and equipment	$329,790	$326,824
Leasehold improvements	93,665	93,665
Capitalized new product development costs	0	15,000
Less: Accumulated depreciation	-135,221	-114,050
Less: Allowance for loss on impairment	-158,292	-158,292
Property, plant, and equipment, net	$129,942	$163,147

PROPERTY_PLANT_AND_EQUIPMENT_D1

PROPERTY, PLANT, AND EQUIPMENT (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Depreciation	$21,171	$4,869

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Patents	$4,794,853	$4,794,853
Capitalized license costs	200,000	0
Software	105,839	105,839
Less: Accumulated amortization	-608,985	-505,059
Intangible assets, net	$4,491,707	$4,395,633

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
2014 (includes the remainder of the year)	$313,525	'
2015	412,212	'
2016	404,951	'
2017	393,982	'
2018	393,982	'
Thereafter	2,573,055	'
Intangible assets, net	$4,491,707	$4,395,633

INTANGIBLE_ASSETS_Details_Text

INTANGIBLE ASSETS (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Computer Software, Intangible Asset [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	$8,761	$4,678
Finite-Lived Intangible Asset, Useful Life	'3 years	'
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	93,497	89,398
Patents [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'9 years	'
Patents [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Asset, Useful Life	'14 years	'
Laboratory software [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived Intangible Assets Acquired	58,000	'
Finite-Lived Intangible Asset, Useful Life	'3 years	'
Company Website [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived Intangible Assets Acquired	31,500	'
Software License Arrangement [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization of Intangible Assets	$1,668	$0
Finite-Lived Intangible Asset, Useful Life	'10 years	'

PAYROLL_LIABILITIES_Details

PAYROLL LIABILITIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Payroll Liabilities [Line Items]	'	'
Accrued bonus payable	$116,031	$408,362
Accrued payroll liabilities	67,003	48,232
Accrued payroll tax liabilities	12,862	19,883
Payroll liabilities	$195,896	$476,477

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)

Sep. 30, 2012

Dec. 31, 2011

Dec. 31, 2011

Jun. 30, 2011

Sep. 30, 2012

Dec. 31, 2011

Dec. 31, 2011

Jun. 30, 2011

Sep. 30, 2012

Dec. 31, 2011

Dec. 31, 2011

Jun. 30, 2011

Placement Agent1 [Member]

Placement Agent2 [Member]

Investor Warrants [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 2 [Member]

Placement Agent1 [Member]

Placement Agent2 [Member]

Investor Warrants [Member]

Placement Agent1 [Member]

Placement Agent2 [Member]

Investor Warrants [Member]

Share Based Payment Award Stock Warrants Valuation Assumptions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Indexed shares

325,000

788,520

788,520

5,256,800

'

'

'

'

'

'

'

'

Exercise price

$5

$1.60

$1.25

$1.60

'

'

'

'

'

'

'

'

Significant assumptions:

'

'

'

'

'

'

'

'

'

'

'

'

Stock price

'

'

'

'

$5

[1]

$0.91

[2]

$0.91

[2]

$0.91

[2]

'

'

'

'

Remaining term

'

'

'

'

'5 years

[3]

'6 years

[3]

'6 years

[3]

'6 years

[3]

'

'

'

'

Risk free rate

'

'

'

'

'

'

'

'

0.62%

[4]

1.12%

[4]

1.12%

[4]

2.49%

[4]

Expected volatility

'

'

'

'

56.54%

[5]

54.21%

[5]

54.21%

[5]

53.55%

[5]

'

'

'

'

[1]

Stock price- The Companybs common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).

[2]

Stock price- The Companybs common stock was not publicly traded at the time the Warrants were issued. Therefore, the stock price was determined implicitly from an iterative process in order for the combined fair value of the common stock and the warrants to equal the amount of proceeds received in the Private Placement, based upon the assumption that the Private Placement was the result of an armbs length transaction.

[3]

Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.

[4]

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

[5]

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entitiesb share prices in calculating the expected volatility appropriate to the Company.

STOCKHOLDERS_EQUITY_Details_1

STOCKHOLDERS' EQUITY (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2012
Share Based Payment Award Stock Warrants Valuation Assumptions [Line Items]	'
Indexed shares	325,000
Exercise price	$5
Fair Value, Inputs, Level 3 [Member]	'
Significant assumptions:	'
Stock price	$5	[1]
Remaining term	'5 years	[2]
Expected volatility	56.54%	[3]
Fair Value, Inputs, Level 2 [Member]	'
Significant assumptions:	'
Risk free rate	0.62%	[4]
[1]	Stock price- The Companybs common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).
[2]	Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.
[3]	Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entitiesb share prices in calculating the expected volatility appropriate to the Company.
[4]	Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

STOCKHOLDERS_EQUITY_Details_2

STOCKHOLDERS' EQUITY (Details 2) (USD $)

Sep. 30, 2012

Sep. 30, 2012

Jan. 29, 2014

Jan. 29, 2014

Jan. 29, 2014

Jan. 29, 2014

Jan. 29, 2014

Jan. 29, 2014

Jan. 29, 2014

Jan. 29, 2014

Fair Value, Inputs, Level 3 [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Investor Warrants 2014 [Member]

Investor Warrants 2014 [Member]

Investor Warrants 2014 [Member]

Investor Warrants 2014 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 1 [Member]

Share Based Payment Award Stock Warrants Valuation Assumptions [Line Items]

'

'

'

'

'

'

'

'

'

'

Indexed shares

325,000

'

175,027

'

'

'

1,166,849

'

'

'

Exercise price

$5

'

$3

'

'

'

$3

'

'

'

Significant assumptions:

'

'

'

'

'

'

'

'

'

'

Stock price

'

$5

[1]

'

'

'

$2.47

[2]

'

'

'

$2.50

[2]

Remaining term

'

'5 years

[3]

'

'5 years

[3]

'

'

'

'5 years

[3]

'

'

Risk free rate

'

'

'

'

1.42%

[4]

'

'

'

1.45%

[4]

'

Expected volatility

'

56.54%

[5]

'

37.95%

[6]

'

'

'

37.96%

[6]

'

'

[1]

Stock price- The Companybs common stock was not publicly traded at the time the Acueity Warrants were issued. Therefore, the stock price was determined at the offering price of the then contemplated initial public offering, for which the registration statement on Form S-1 (File No. 333-179500) was subsequently declared effective by the Securities and Exchange Commission on November 7, 2012, and a prospectus was subsequently filed pursuant to Rule 424(b)(4) on November 9, 2012 (see Note 14).

[2]

Stock price- The Fair value of Companybs common was derived from the closing prices in NASDAQ Capital Market as of the issuance.

[3]

Remaining term- The Company does not have a history to develop the expected term for its warrants. Accordingly, the Company expected that the Initial Exercise Date would occur within one year from the date of issuance plus the contractual term in the calculations.

[4]

Risk-free rate- The risk-free rate of return reflects the interest rate for United States Treasury Note with similar time-to-maturity to that of the warrants.

[5]

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified seven public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entitiesb share prices in calculating the expected volatility appropriate to the Company.

[6]

Expected volatility- We did not have a historical trading history sufficient to develop an internal volatility rate for use in the model. As a result, as required by ASC 718-10-30, the Company has accounted for the warrants using the calculated value method. The Company identified five public entities in the similar industry for which share price information was available, and considered the historical volatilities of those public entitiesb share prices in calculating the expected volatility appropriate to the Company.

STOCKHOLDERS_EQUITY_Details_Te

STOCKHOLDERS' EQUITY (Details Textual) (USD $)

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Sep. 28, 2010

Mar. 31, 2014

Dec. 31, 2013

Sep. 28, 2010

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Jan. 29, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2011

Jun. 30, 2011

Dec. 31, 2011

Mar. 31, 2014

Dec. 31, 2011

Dec. 31, 2011

Sep. 30, 2012

Apr. 29, 2009

Apr. 29, 2009

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Apr. 29, 2009

Apr. 29, 2009

Apr. 29, 2009

Apr. 29, 2009

Stock Option and Incentive Plan 2010 [Member]

Stock Option and Incentive Plan 2010 [Member]

Stock Option and Incentive Plan 2010 [Member]

Stock Option and Incentive Plan 2010 [Member]

Stock Option and Incentive Plan 2010 [Member]

2014 Public Offering [Member]

2014 Public Offering [Member]

2011 Private Placement [Member]

2013 Public Offering [Member]

Acuiety Transaction [Member]

outside consulting firm [Member]

Warrant [Member]

Private Placement [Member]

Securities Purchase Agreements, Investor Warrants [Member]

Placement Agent Additional Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent Warrants [Member]

Placement Agent2 [Member]

Acueity Warrants [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Placement Agent [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Ensisheim Partners Llc [Member]

Ensisheim Partners Llc [Member]

Manistee Ventures Llc [Member]

Manistee Ventures Llc [Member]

Restricted Stock [Member]

Prior to Reverse Share Split on September 28, 2010 [Member]

2011 Private Placement [Member]

2013 Public Offering [Member]

2011 Private Placement [Member]

2013 Public Offering [Member]

Prior to Reverse Share Split on September 28, 2010 [Member]

Prior to Reverse Share Split on September 28, 2010 [Member]

Stockholder's Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Shares Authorized

'

85,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

'

75,000,000

75,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share (in dollars per share)

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share (in dollars per share)

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' Equity, Reverse Stock Split

'1-for-2.26332

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Issued

'

24,428,568

18,574,334

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

883,662

2,000,000

'

'

'

'

'

1,767,316

4,000,000

1,325,487

3,000,000

Common Stock, Value, Issued

'

$24,429

$18,574

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$12,000

'

'

'

'

'

'

$24,000

'

$18,000

'

Stock Issued During Period, Shares, Acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

862,500

'

'

'

'

'

'

'

'

'

'

'

Equity Issuance, Per Share Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

$0.01

'

'

'

'

'

$0.01

$0.01

$0.01

$0.01

Sale of Stock, Number of Shares Issued in Transaction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,256,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,571,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash Fee Equals to Percentage of Gross Proceeds from Sale of Common Stock and Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

7.00%

'

'

'

'

'

'

'

'

Percentage of Non-Accountable Expense Allowance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

Fees and Commissions, Other

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

857,230

'

'

'

'

'

'

'

'

980,151

'

'

'

'

'

'

'

'

Exercise Price of Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.60

'

'

$1.25

$1.25

$5

'

'

$3

'

'

'

'

'

'

'

'

Fair Value of Warrants (in dollars per warrant)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.72

'

$0.34

$0.29

$0.70

$0.34

'

$2.35

'

'

'

'

'

'

'

'

'

'

'

Initial Fair Value of Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

834,986

495,876

1,808,025

228,712

121,707

267,164

'

762,353

'

'

121,707

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

897,617

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

'

'

'

'

'

'

1,166,849

4,292,050

242,027

325,000

47,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,256,800

'

'

'

'

'

'

'

175,027

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

6,073,426

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

788,520

'

788,520

'

325,000

'

'

'

'

'

'

'

'

'

'

'

Shares, Issued

'

'

'

'

'

'

'

'

5,834,234

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued, Price Per Share

'

'

'

'

'

'

'

'

$2.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance Initial Public Offering

'

'

'

'

'

'

'

'

$14,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders Equity Note, Stock Split

'

'

'

'

'

'

'

'

'

'Each unit consists of one share of common stock and a warrant to purchase 0.20 of a share of common stock (the 2014 Warrants).

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Exercisable Per Share

'

'

'

'

'

'

'

'

'

$3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Callable Per Share

'

'

'

'

'

'

'

'

'

$6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

'

3

'

'

5

4.24

'

'

'

'

'

'

'

'

'

'

'

1.25

2.12

1.6

12.43

'

'

'

'

Shares held in Employee Stock Option Plan, Suspense Shares

'

'

'

1,000,000

742,973

516,774

450,275

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

'

311,669

'

'

334,397

'

'

22,728

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Reverse Stock Splits

'

'

'

2,263,320

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONCENTRATION_OF_CREDIT_RISK_D

CONCENTRATION OF CREDIT RISK (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Concentration Risk [Line Items]	'	'
Cash, FDIC Insured Amount	$250,000	'
Cash, Uninsured Amount	$16,340,951	$6,092,161

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2013
Operating Leased Assets [Line Items]	'
2014 (remainder of the year)	$247,939
2015	276,805
2016	255,845
2017	0
2018	0
Thereafter	0
Total minimum lease payments	$780,589

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)

3 Months Ended

59 Months Ended

3 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2013

Jun. 30, 2011

Mar. 31, 2014

Mar. 04, 2011

Mar. 31, 2012

Dec. 09, 2011

Dec. 09, 2011

Dec. 09, 2011

Jul. 31, 2013

Mar. 31, 2014

Mar. 20, 2014

Mar. 24, 2014

Mar. 24, 2014

Mar. 24, 2014

A5 Genetics KFT [Member]

A5 Genetics KFT [Member]

Affymetrix In [Member]

Affymetrix In [Member]

Robert Kelly [Member]

Robert Kelly [Member]

Lease Agreement March 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement December 2011 [Member]

Lease Agreement March 2014 [Member]

Lease Agreement March 2014 [Member]

Lease Agreement March 2014 [Member]

Lease Agreement March 2014 [Member]

OwnerChip Program Agreement [Member]

OwnerChip Program Agreement [Member]

Sanders Properties, Llc [Member]

Fred Hutchinson Research Center [Member]

Fred Hutchinson Research Center [Member]

Fred Hutchinson Research Center [Member]

Fred Hutchinson Research Center [Member]

ARE LLC [Member]

ARE LLC [Member]

Sanders Properties, Llc [Member]

ARE LLC [Member]

ARE LLC [Member]

ARE LLC [Member]

Monthly Rent For Period From February 24, 2012 To August 31, 2012 [Member]

Monthly Rent For Period From September 1, 2012 To August 31, 2013 [Member]

Monthly Rent For Period From September 1, 2013 To November 29, 2014 [Member]

Monthly Rent From December 2014 Through November 2015 [Member]

Monthly Rent From December 2015 Through November 2016 [Member]

COMMITMENTS AND CONTINGENCIES [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Monthly Lease Rent

'

'

'

'

'

'

'

'

'

'

$1,100

'

$16,395

$19,923

$20,548

$4,800

'

$1,150

'

$22,736

$23,258

Security Deposit

61,309

'

61,309

36,446

'

'

'

'

'

'

1,500

32,789

'

'

'

'

'

'

25,000

'

'

Operating Leases, Rent Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

65,605

'

'

'

'

Loss Contingency, Damages Sought, Value

'

'

'

'

'

'

'

'

450,000

'

'

'

'

'

'

'

'

'

'

'

'

Payments for Software

'

'

'

'

'

'

21,590

94,723

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Obligation

'

'

'

'

'

'

647,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contract Receivable, Due in Rolling Year Two

'

'

'

'

'

'

51,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreed To Forfeit

'

'

'

'

'

'

'

'

'

2,111,600

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency, Accrual, Current

96,201

'

96,201

211,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease Expiration Date, Descriptions

'

'

'

'

'

'

'

'

'

'

'The lease terms are from April 1, 2011 through March 31, 2014.

'

'period from February 24, 2012 to August 31, 2012

'period from September 1, 2012 to August 31, 2013

'period from September 1, 2013 to November 29, 2014

'The lease is from August 2013 through November 2014

'

'lease through March 31, 2015

'November 2014, through November 30, 2016

'from December 2014 through November 2015

'from December 2015 through November 2016

Recall expenses Actual

339,042

'

339,042

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of Services, Licenses and Services

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional License Fee Amount Paid

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional License Fee Obligation To Pay For Future Milestones

'

'

'

'

1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Expense

'

'

'

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost of Services

$0

$47,599

$141,509

'

$65

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

STOCK_BASED_COMPENSATION_Detai

STOCK BASED COMPENSATION (Details) (USD $)

Sep. 30, 2012

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Employees [Member]

Employees [Member]

Employees [Member]

Employees [Member]

Employees [Member]

Employees [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Employees and Officers [Member]

Officers [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Chief Executive Officer and Chief Scientific Officer [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Stock Option [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Share Based Payment Award Stock Options Valuation Assumption [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of grant

'

8-Jan-14

'

'

'

'

'

'

'

'

8-Jan-14

1-Mar-14

'

'

'

31-Mar-13

Date of grant start

'

'

1-Jan-13

'

'

'

'

1-Jan-13

'

'

'

'

31-May-13

'

'

'

Date of grant end

'

'

31-Dec-13

'

'

'

'

30-Jun-13

'

'

'

'

31-Oct-13

'

'

'

Fair value of common stock on date of grant

'

$2.20

[1]

'

'

$2.05

[1]

'

$5.19

[1]

'

$4.11

[1]

$4.58

[1]

$2.20

[1]

$2.20

[1]

'

$2.04

[1]

$6.59

[1]

$6.57

[1]

Exercise price of the options

$5

$2.20

'

'

$2.05

'

$5.19

'

$4.11

$4.58

$2.20

$2.20

'

$2.04

$6.59

$6.57

Expected life of the options (years)

'

'6 years 22 days

'

'

'6 years 1 month 2 days

'

'6 years 1 month 10 days

'

'5 years

'6 years 1 month 10 days

'6 years 22 days

'5 years 1 month 2 days

'

'5 years

'5 years 3 months 22 days

'5 years

Dividend yield

'

0.00%

0.00%

'

'

'

'

0.00%

'

'

0.00%

0.00%

0.00%

'

'

0.00%

Expected volatility

'

'

'

41.70%

40.73%

41.72%

41.81%

'

40.96%

41.05%

41.70%

38.68%

'

41.06%

41.53%

47.09%

Risk-free interest rate

'

2.11%

'

'

1.73%

'

1.97%

'

1.03%

1.36%

2.11%

1.53%

'

0.73%

1.49%

1.13%

Expected forfeiture per year (%)

'

10.00%

10.00%

'

'

'

'

10.00%

'

'

10.00%

10.00%

10.00%

'

'

0.00%

Weighted-average fair value of the options (per unit)

'

0.95

'

'

0.878

'

2.18

'

1.69

1.89

0.95

0.8

'

0.79

2.49

2.7

[1]

The fair values of the Company's common stock were derived from the closing prices on the NASDAQ Capital Market as of the dates of grant.

STOCK_BASED_COMPENSATION_Detai1

STOCK BASED COMPENSATION (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014
Share Based Compensation Stock Options Activity [Line Items]	'
Number of Underlying Shares, Outstanding as of January 1, 2014 (in shares)	2,282,719
Number of Underlying Shares, Granted (in shares)	311,669
Number of Underlying Shares, Expired (in shares)	0
Number of Underlying Shares, Forfeited (in shares)	-61,221
Number of Underlying Shares, Exercised (in shares)	0
Number of Underlying Shares, Outstanding as of March 31, 2014 (in shares)	2,533,167
Number of Underlying Shares, Exercisable as of March 31, 2014 (in shares)	1,253,137
Number of Underlying Shares, Vested and expected to vest (in shares)	2,355,778	[1]
Weighted-Average Exercise Price Per Share, Outstanding as of January 1, 2014 (in dollars per share)	$4.43
Weighted-Average Exercise Price Per Share, Granted (in dollars per share)	$2.20
Weighted-Average Exercise Price Per Share, Expired (in dollars per share)	$0
Weighted-Average Exercise Price Per Share, Forfeited (in dollars per share)	$4.70
Weighted-Average Exercise Price Per Share, Exercised (in dollars per share)	$0
Weighted-Average Exercise Price Per Share, Outstanding as of March 31, 2014 (in dollars per share)	$4.15
Weighted-Average Exercise Price Per Share, Exercisable as of March 31, 2014 (in dollars per share)	$4.47
Weighted-Average Exercise Price Per Share, Vested and expected to vest (in dollars per share)	$4.18	[1]
Weighted-Average Contractual Life Remaining in Years, Outstanding as of March 31, 2014	'7 years 10 months 10 days
Weighted-Average Contractual Life Remaining in Years, Exercisable as of as of March 31, 2014	'6 years 6 months 7 days
Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest	'7 years 9 months 4 days	[1]
Aggregate Intrinsic Value, Outstanding as of March 31, 2014	$107,800
Aggregate Intrinsic Value, Exercisable as of March 31, 2014	107,800
Aggregate Intrinsic Value, Vested and expected to vest (1)	$107,800
[1]	vested shares and unvested shares after a forfeiture rate is applied.

STOCK_BASED_COMPENSATION_Detai2

STOCK BASED COMPENSATION (Details Textual) (USD $)	0 Months Ended	3 Months Ended		59 Months Ended
	Oct. 10, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Stock-based Compensation [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	'	$230,181	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	$2.20	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	24,510	22,728	'	'
Stock Issued During Period, Value, Restricted Stock Award, Gross	50,000	50,000	'	'
Share-based Compensation, Total	'	230,181	274,512	1,966,205
Restricted Stock [Member]	'	'	'	'
Stock-based Compensation [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	'	$16,611	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$2.04	$2.20	'	'

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Subsequent Event [Line Items]	'
Stock option grant	311,669
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Stock option grant	150,000
Subsequent Event [Member] | Steven C. Quay, Ph.D., M.D [Member] | Chief Executive Officer [Member]	'
Subsequent Event [Line Items]	'
Annual Base Salary	500,000
Annual bonus potential percentage	50.00%
Stock option grant	250,000
Subsequent Event [Member] | Kyle Guse, CPA, J.D [Member] | Chief Financial Officer [Member]	'
Subsequent Event [Line Items]	'
Annual Base Salary	350,000
Annual bonus potential percentage	45.00%
Stock option grant	200,000
Subsequent Event [Member] | Shu-Chih Chen, Ph.D [Member] | Chief Scientific Officer [Member]	'
Subsequent Event [Line Items]	'
Annual Base Salary	350,000
Annual bonus potential percentage	40.00%
Stock option grant	125,000

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014
Subsequent Event [Line Items]	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	311,669
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Salary Adjustments For Senior Officers	143,438
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	150,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value	1.22